Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...

Fujifilm announced an additional investment of $1.2 billion in its large-scale cell culture contract development and manufacturing organization (CDMO) business to further...

Fujifilm Diosynth Biotechnologies unveiled its new $2 billion large-scale cell culture manufacturing facility in Holly Springs, North Carolina, US.

Fujifilm is preparing to invest $1.6 billion to ramp up the cell culture manufacturing services of its CDMO subsidiary Fujifilm Diosynth Biotechnologies.

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...

Fujifilm Diosynth Biotechnologies has chosen Holly Springs in North Carolina as the site of its new large-cell culture production site in the US. The company first...